The United States Department of Justice has recently opposed biopharmaceutical company Gilead Sciences’ attempt to alter a previous judgment from a Delaware federal court. This prior judgment determined that two of the firm’s medications used in its HIV prevention regimen, directly infringed on patents held by the government that have been subsequently invalidated.
The Department of Justice defended its position by stating Gilead’s attempt to revise the judgment is both improper and unnecessary. The outcome of this case could have significant implications both for the specific scope of HIV treatment patent protections and for patent disputes more generally within the pharmaceutical industry.
Read more on Law360 about the U.S. Department of Justice’s stance on Gilead Sciences’ efforts to modify the judgment.